Nanexa Stock Skyrockets More Than 100% After Signing Drug Deal With Wegovy Maker Novo Nordisk

Under the deal, Novo gets the right to use PharmaShell in as many as five development programs for peptide-based medicines targeting obesity, type 2 diabetes and other cardiometabolic diseases.